Changes in lipid abundance are associated with disease progression and treatment response in chronic <em>Trypanosoma cruzi</em> infection

Background: Chagas disease, caused by the parasite Trypanosoma cruzi, is a zoonosis that affects more than seven million people. Current limitations on the diagnosis of the disease hinder the prognosis of patients and the evaluation of treatment efficacy, slowing the development of new therapeutic o...

Full description

Bibliographic Details
Authors: Gabaldón Figueira, Juan Carlos, Ros Lucas, Albert, Martinez-Peinado, Nieves, Blackburn, Gavin, Losada Galvan, Irene, Posada, Elizabeth, Ballart Ferrer, J. Cristina, Escabia, Elisa, Capellades, Jordi, Yanes, Oscar, Pinazo, Maria-Jesus, Gascón i Brustenga, Joaquim, Alonso Padilla, Julio
Format: article
Status:Published version
Publication Date:2024
Country:España
Institution:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repository:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/222364
Online Access:https://hdl.handle.net/2445/222364
Access Level:Open access
Keyword:Malaltia de Chagas
Protists
Esfingolípids
Metabolòmica
Chagas' disease
Protista
Sphingolipids
Metabolomics
Description
Summary:Background: Chagas disease, caused by the parasite Trypanosoma cruzi, is a zoonosis that affects more than seven million people. Current limitations on the diagnosis of the disease hinder the prognosis of patients and the evaluation of treatment efficacy, slowing the development of new therapeutic options. The infection is known to disrupt several host metabolic pathways, providing an opportunity for the identification of biomarkers. Methods: The metabolomic and lipidomic profiles of a cohort of symptomatic and asymptomatic patients with T. cruzi infection and a group of uninfected controls were analysed using liquid chromatography/mass spectrometry. Differences among all groups and changes before and after receiving anti-parasitic treatment across those with T. cruzi infection were explored. Results: Three lipids were found to differentiate between symptomatic and asymptomatic participants: 10-hydroxydecanoic acid and phosphatidylethanolamines PE(18:0/20:4) and PE(18:1/20:4). Additionally, sphinganine, 4-hydroxysphinganine, hexadecasphinganine, and other sphingolipids showed post-treatment abundance similar to that in non-infected controls. Conclusions: These molecules hold promise as potentially useful biomarkers for monitoring disease progression and treatment response in patients with chronic T. cruzi infection.

Similar Items